Integrating omics and network pharmacology reveals the anti-constipation role of chitosan with different molecular weights in constipated mice

Yuxuan Liang; Xiaoyi Wei; Jie Deng; Cheng Peng; Rui Ren; Yanying Luo; Jiexin Zhang; Xiaoqun Wei; Gary Hardiman; Yuanming Sun; Hong Wang

doi:10.1016/j.ijbiomac.2023.123930

Integrating omics and network pharmacology reveals the anti-constipation role of chitosan with different molecular weights in constipated mice

Yuxuan Liang, Xiaoyi Wei, Jie Deng, Cheng Peng, Rui Ren, Yanying Luo, Jiexin Zhang, Xiaoqun Wei, Gary Hardiman, Yuanming Sun, Hong Wang

School of Biological Sciences

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

This study aimed to reveal the constipation-relieving role of chitosan (COS) with different molecular weights (1 kDa, 3 kDa and 244 kDa). Compared with COS3K (3 kDa) and COS240K (244 kDa), COS1K (1 kDa) more significantly accelerated gastrointestinal transit and defecation frequency. These differential effects were reflected in the regulation of specific gut microbiota (Desulfovibrio, Bacteroides, Parabacteroides and Anaerovorax) and short-chain fatty acids (propionic acid, butyric acid and valeric acid). RNA-sequencing found that the differential expressed genes (DEGs) caused by different molecular weights of COS were mainly enriched in intestinal immune-related pathways, especially cell adhesion molecules. Furthermore, network pharmacology revealed two candidate genes (Clu and Igf2), which can be regarded as the key molecules for the differential anti-constipation effects of COS with different molecular weights. These results were further verified by qPCR. In conclusion, our results provide a novel research strategy to help understand the differences in the anti-constipation effects of chitosan with different molecular weights.

Original language	English
Article number	123930
Number of pages	11
Journal	International Journal of Biological Macromolecules
Volume	235
Early online date	08 Mar 2023
DOIs	https://doi.org/10.1016/j.ijbiomac.2023.123930
Publication status	Published - 30 Apr 2023

Keywords

Network pharmacology
Constipation
Chitosan
RNA-sequencing
Molecular weight

Access to Document

10.1016/j.ijbiomac.2023.123930Licence: Unspecified

Cite this

Liang, Y., Wei, X., Deng, J., Peng, C., Ren, R., Luo, Y., Zhang, J., Wei, X., Hardiman, G., Sun, Y., & Wang, H. (2023). Integrating omics and network pharmacology reveals the anti-constipation role of chitosan with different molecular weights in constipated mice. International Journal of Biological Macromolecules, 235, Article 123930. https://doi.org/10.1016/j.ijbiomac.2023.123930

@article{0c6dfd5af2f94b6ba795e6b5c0b5d77d,

title = "Integrating omics and network pharmacology reveals the anti-constipation role of chitosan with different molecular weights in constipated mice",

abstract = "This study aimed to reveal the constipation-relieving role of chitosan (COS) with different molecular weights (1 kDa, 3 kDa and 244 kDa). Compared with COS3K (3 kDa) and COS240K (244 kDa), COS1K (1 kDa) more significantly accelerated gastrointestinal transit and defecation frequency. These differential effects were reflected in the regulation of specific gut microbiota (Desulfovibrio, Bacteroides, Parabacteroides and Anaerovorax) and short-chain fatty acids (propionic acid, butyric acid and valeric acid). RNA-sequencing found that the differential expressed genes (DEGs) caused by different molecular weights of COS were mainly enriched in intestinal immune-related pathways, especially cell adhesion molecules. Furthermore, network pharmacology revealed two candidate genes (Clu and Igf2), which can be regarded as the key molecules for the differential anti-constipation effects of COS with different molecular weights. These results were further verified by qPCR. In conclusion, our results provide a novel research strategy to help understand the differences in the anti-constipation effects of chitosan with different molecular weights.",

keywords = "Network pharmacology, Constipation, Chitosan, RNA-sequencing, Molecular weight",

author = "Yuxuan Liang and Xiaoyi Wei and Jie Deng and Cheng Peng and Rui Ren and Yanying Luo and Jiexin Zhang and Xiaoqun Wei and Gary Hardiman and Yuanming Sun and Hong Wang",

year = "2023",

month = apr,

day = "30",

doi = "10.1016/j.ijbiomac.2023.123930",

language = "English",

volume = "235",

journal = "International Journal of Biological Macromolecules",

issn = "0141-8130",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Integrating omics and network pharmacology reveals the anti-constipation role of chitosan with different molecular weights in constipated mice

AU - Liang, Yuxuan

AU - Wei, Xiaoyi

AU - Deng, Jie

AU - Peng, Cheng

AU - Ren, Rui

AU - Luo, Yanying

AU - Zhang, Jiexin

AU - Wei, Xiaoqun

AU - Hardiman, Gary

AU - Sun, Yuanming

AU - Wang, Hong

PY - 2023/4/30

Y1 - 2023/4/30

N2 - This study aimed to reveal the constipation-relieving role of chitosan (COS) with different molecular weights (1 kDa, 3 kDa and 244 kDa). Compared with COS3K (3 kDa) and COS240K (244 kDa), COS1K (1 kDa) more significantly accelerated gastrointestinal transit and defecation frequency. These differential effects were reflected in the regulation of specific gut microbiota (Desulfovibrio, Bacteroides, Parabacteroides and Anaerovorax) and short-chain fatty acids (propionic acid, butyric acid and valeric acid). RNA-sequencing found that the differential expressed genes (DEGs) caused by different molecular weights of COS were mainly enriched in intestinal immune-related pathways, especially cell adhesion molecules. Furthermore, network pharmacology revealed two candidate genes (Clu and Igf2), which can be regarded as the key molecules for the differential anti-constipation effects of COS with different molecular weights. These results were further verified by qPCR. In conclusion, our results provide a novel research strategy to help understand the differences in the anti-constipation effects of chitosan with different molecular weights.

AB - This study aimed to reveal the constipation-relieving role of chitosan (COS) with different molecular weights (1 kDa, 3 kDa and 244 kDa). Compared with COS3K (3 kDa) and COS240K (244 kDa), COS1K (1 kDa) more significantly accelerated gastrointestinal transit and defecation frequency. These differential effects were reflected in the regulation of specific gut microbiota (Desulfovibrio, Bacteroides, Parabacteroides and Anaerovorax) and short-chain fatty acids (propionic acid, butyric acid and valeric acid). RNA-sequencing found that the differential expressed genes (DEGs) caused by different molecular weights of COS were mainly enriched in intestinal immune-related pathways, especially cell adhesion molecules. Furthermore, network pharmacology revealed two candidate genes (Clu and Igf2), which can be regarded as the key molecules for the differential anti-constipation effects of COS with different molecular weights. These results were further verified by qPCR. In conclusion, our results provide a novel research strategy to help understand the differences in the anti-constipation effects of chitosan with different molecular weights.

KW - Network pharmacology

KW - Constipation

KW - Chitosan

KW - RNA-sequencing

KW - Molecular weight

U2 - 10.1016/j.ijbiomac.2023.123930

DO - 10.1016/j.ijbiomac.2023.123930

M3 - Article

C2 - 36889616

SN - 0141-8130

VL - 235

JO - International Journal of Biological Macromolecules

JF - International Journal of Biological Macromolecules

M1 - 123930

ER -

Integrating omics and network pharmacology reveals the anti-constipation role of chitosan with different molecular weights in constipated mice

Abstract

Keywords

Access to Document

Fingerprint

Cite this